News from biotrends research group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 02, 2010, 08:00 ET
May 26, 2010, 09:26 ET

Use of Centocor-Ortho Biotech's Stelara (Ustekinumab) is on an Upswing as Familiarity Increases and Experience With the Product Produces Excellent Outcomes, According to U.S. Dermatologists

 BioTrends released the final wave of LaunchTrends®: Stelara, a three wave syndicated report that has been tracking the uptake of the...

May 13, 2010, 09:00 ET

Despite Safety Concerns, Actemra Usage Increases Among TNF-Refractory Patients Who Have Failed One or Two Biologics

BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA.  Actemra...

May 06, 2010, 08:00 ET

New Study By BioTrends Highlights the Risk of TNF-alpha Inhibitors of Losing Patient Share To Alternative Mechanism Agents in the Treatment of Rheumatoid Arthritis

BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis.  This report covers...

Apr 29, 2010, 08:00 ET

The Phosphate Binder Market is Currently Stable Despite Talks of Major Changes in January 2011 Once the Dialysis Bundled Payment System Takes Effect

BioTrends Research Group, Inc. recently published two syndicated reports focused on the management of bone and mineral metabolism in the US....

Apr 27, 2010, 08:00 ET

Changes Brewing in the Renal Anemia Market, According to Two Recent Publications from BioTrends

BioTrends Research Group, Inc. is pleased to announce the recent release of two syndicated reports focused on the management of renal anemia in the...

Apr 26, 2010, 08:00 ET

Neurologists Eagerly Await New Oral Treatment Options for Multiple Sclerosis Such as EMD Serono's Movectro and Novartis's Gilenia

BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis.  This report covers the use...

Mar 24, 2010, 08:00 ET

As The Dialysis Bundled Payment Plan Draws Near, Medical Directors and Renal Administrators Become More Concerned About Negative Patient Outcomes In ESRD

BioTrends announces the release of the second wave of an on-going series of reports, Special Report: Impact of the Dialysis Bundled Payment System....

Mar 18, 2010, 12:41 ET

Rheumatologists Are Eager to Use Roche-Genentech's ACTEMRA, According to New Study by BioTrends

BioTrends is pleased to announce the publication of a new syndicated report, LaunchTrends®: ACTEMRA.  Actemra (tocilizumab), marketed by...

Feb 18, 2010, 08:00 ET

Stelara Impresses With Efficacy Data and Dosing Convenience, But Safety Concerns Likely to Impact Near Term Uptake

BioTrends published the second wave of LaunchTrends®: Stelara, highlighting dermatology market trends at three months post launch.  The...

Feb 16, 2010, 17:21 ET

Use of AMAG's Feraheme is on the Rise with 23% of Nephrologists Reporting Use of the Product

BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research...

Jan 11, 2010, 17:00 ET

New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)

BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends®: ACTEMRA. Roche, Inc. announced that they received...

Jan 11, 2010, 12:00 ET

Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA

BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S....

Jan 07, 2010, 16:53 ET

Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral Metabolism Practice Patterns Around the Globe

BioTrends Research Group, Inc. recently released its TreatmentTrends®: US Nephrology, EU Nephrology, and Canadian Nephrology publications....

Jan 06, 2010, 16:22 ET

BioTrends Provides Insight into the Global Renal Anemia Market with the Release of Three Nephrology TreatmentTrends Publications

BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrends®: US Nephrology, EU Nephrology, and Canadian...

Dec 23, 2009, 14:00 ET

BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties

BioTrends Research Group, Inc. published a syndicated research report, "TreatmentTrends®: Anemia in the United States," based on primary...

Dec 23, 2009, 12:00 ET

Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey

BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends®: Simponi and Cimzia report. The survey was...

Dec 14, 2009, 17:33 ET

New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis

BioTrends Research Group, Inc. released ChartTrends®: Biologics in Rheumatoid Arthritis, a syndicated publication offering comprehensive...

Nov 25, 2009, 14:32 ET

Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High

BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research...

Nov 23, 2009, 09:30 ET

Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use

BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research...